CADL Historical PE Ratio Notes

— Candel Therapeutics (ticker symbol: CADL) is a clinical-stage biopharmaceutical company specializing in the development & commercialization of novel immunotherapies for cancer. The company's primary focus lies in leveraging viral-based therapies to stimulate the body's immune system to target & destroy cancer cells, with candidates such as CAN-2409 & CAN-3110 advancing through clinical trials targeting various solid tumor types. Because Candel Therapeutics is pre-revenue and heavily investment-focused, it often reports negative earnings, which means you will notice that its historical PE ratio data may either be negative or not applicable (N/A) in many periods. This is typical for early-stage biotechs, where scientific progress & future commercial potential, rather than current earnings, have a much larger impact on stock price, resulting in unusual or uninformative PE ratios. When reviewing historical charts & tables related to price, earnings, and PE ratio, it's crucial to recognize that fluctuations in CADL's ratios are more reflective of market sentiment about future pipeline successes & fundraising than changes in ongoing profitability. As a result, traditional valuation through PE ratio is often less meaningful, and investors tend to weigh clinical milestones, regulatory news, & partnership announcements more heavily than near-term financial performance.

On this page we presented the CADL Historical PE Ratio information for Candel Therapeutics' stock. The average CADL historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 10.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CADL historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CADL historical PE result, against the recent PE: when this page was posted on 8/19/2026, the most recent closing price for CADL had been 13.50, and the most recent quarterly earnings result, annualized, was 0.52. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent CADL PE on 8/19/2026 based on annualized quarterly EPS was 26.0. Based on CADL's history, that recent PE is elevated relative to the historical average, with the recent PE 150.0% higher than the historical average PE across our data set for Candel Therapeutics.

For self directed investors doing their due diligence on CADL or any other given stock, valuation analysis for CADL can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Candel Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CADL. Thanks for visiting, and the next time you need to research CADL Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.